Free Trial

Calamos Advisors LLC Grows Holdings in Guardian Pharmacy Services, Inc. (NYSE:GRDN)

Guardian Pharmacy Services logo with Medical background

Calamos Advisors LLC lifted its stake in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) by 61.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,919 shares of the company's stock after purchasing an additional 15,194 shares during the period. Calamos Advisors LLC owned 0.06% of Guardian Pharmacy Services worth $849,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Rhumbline Advisers purchased a new stake in shares of Guardian Pharmacy Services during the 4th quarter valued at approximately $149,000. Bank of New York Mellon Corp purchased a new stake in shares of Guardian Pharmacy Services during the 4th quarter valued at approximately $276,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Guardian Pharmacy Services during the 4th quarter valued at approximately $544,000. Royce & Associates LP raised its position in shares of Guardian Pharmacy Services by 185.3% during the 4th quarter. Royce & Associates LP now owns 214,000 shares of the company's stock valued at $4,336,000 after buying an additional 139,000 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of Guardian Pharmacy Services during the 4th quarter valued at approximately $81,000.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on GRDN shares. Raymond James Financial set a $28.00 target price on Guardian Pharmacy Services and gave the company an "outperform" rating in a research report on Wednesday, May 14th. Wall Street Zen lowered Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, Truist Financial reissued a "buy" rating and issued a $28.00 target price (up previously from $25.00) on shares of Guardian Pharmacy Services in a research report on Monday, May 19th.

View Our Latest Stock Analysis on GRDN

Insider Activity

In other Guardian Pharmacy Services news, insider Fred Burke sold 138,705 shares of Guardian Pharmacy Services stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $20.16, for a total value of $2,796,292.80. Following the transaction, the insider owned 413,019 shares in the company, valued at $8,326,463.04. This trade represents a 25.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director William E. Bindley sold 651,454 shares of Guardian Pharmacy Services stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $20.16, for a total transaction of $13,133,312.64. Following the completion of the transaction, the director owned 1,939,817 shares in the company, valued at approximately $39,106,710.72. This trade represents a 25.14% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,344,912 shares of company stock valued at $228,713,426 in the last 90 days. Insiders own 63.71% of the company's stock.

Guardian Pharmacy Services Price Performance

Shares of GRDN traded down $0.20 during mid-day trading on Thursday, hitting $20.89. 124,379 shares of the company's stock were exchanged, compared to its average volume of 185,571. Guardian Pharmacy Services, Inc. has a fifty-two week low of $14.16 and a fifty-two week high of $26.91. The business's 50 day moving average is $22.16 and its two-hundred day moving average is $21.49.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.21 EPS for the quarter, missing the consensus estimate of $0.22 by ($0.01). The firm had revenue of $329.31 million for the quarter, compared to analyst estimates of $321.21 million. On average, equities research analysts anticipate that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current year.

Guardian Pharmacy Services Profile

(Free Report)

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.

Featured Articles

Institutional Ownership by Quarter for Guardian Pharmacy Services (NYSE:GRDN)

Should You Invest $1,000 in Guardian Pharmacy Services Right Now?

Before you consider Guardian Pharmacy Services, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardian Pharmacy Services wasn't on the list.

While Guardian Pharmacy Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines